<DOC>
	<DOC>NCT00718861</DOC>
	<brief_summary>This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis</brief_summary>
	<brief_title>3 yr Efficacy &amp; Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women who have received the 4th and 6th dose of zoledronic acid in study CZOL446H2301E1 Poor kidney, eye, liver health Use of certain therapies for osteoporosis in study CZOL446H2301E1 Abnormal calcium levels Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>post-menopausal</keyword>
</DOC>